Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ARGENTINA GASTRIC CANCER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE\
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 MARKET LIFELINE CURVE
2.7 DBMR MARKET POSITION GRID
2.8 VENDOR SHARE ANALYSIS
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 REGULATIONS OF ARGENTINA GASTRIC CANCER TREATMENT MARKET
7 PIPELINE ANALYSIS FOR ARGENTINA GASTRIC CANCER TREATMENT
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA
8.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
8.1.3 HIGH INCIDENCE OF OBESITY
8.1.4 RECENT ADVANCEMENT IN GASTRIC CANCER TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT
8.3 OPPORTUNITIES
8.3.1 INCREASING DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 OLD AGE CHALLENGES
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
9 IMPACT OF COVID-19 PANDEMIC ON THE ARGENTINA GASTRIC CANCER TREATMENT MARKET
9.1 PRICE IMPACT
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 ADENOCARCINOMA
10.3 GASTROINTESTINAL STROMAL TUMOR
10.4 CARCINOID TUMOR
10.5 LYMPHOMA
10.6 OTHERS
11 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY STAGES
11.1 OVERVIEW
11.2 STAGE III
11.3 STAGE II
11.4 STAGE IV
11.5 STAGE I
11.6 OTHERS
12 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT
12.1 OVERVIEW
12.2 CHEMOTHERAPY
12.2.1 OXALIPLATIN
12.2.2 CISPLATIN
12.2.3 FLUOROURACIL
12.2.4 DOCETAXEL
12.2.5 CAPECITABINE
12.2.6 CARBOPLATIN
12.2.7 EPIRUBICIN
12.2.8 PACLITAXEL
12.2.9 IRINOTECAN
12.2.10 OTHERS
12.3 TARGETED THERAPY
12.3.1 MONOCLONAL ANTIBODY THERAPY
12.3.1.1 TRASTUZUMAB (HERCEPTIN)
12.3.1.2 RAMUCIRUMAB
12.3.2 MULTIKINASE INHIBITORS
12.3.2.1 SUNITINIB
12.3.2.2 REGORAFENIB
12.4 IMMUNE CHECKPOINT INHIBITORS
12.5 OTHERS
13 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 PARENTERAL
13.2.1 INTRAVENOUS
13.2.2 SUBCUTANEOUS
13.2.3 OTHERS
13.3 ORAL
13.3.1 TABLET
13.3.2 CAPSULE
13.3.3 OTHERS
13.4 OTHERS
14 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 RESEARCH & ACADEMIC INSTITUTES
14.5 OTHERS
15 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 OTHERS
16 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: ARGENTINA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 MERCK & CO., INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 ASTRAZENECA
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENTS
18.3 PFIZER INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 ELI LILLY AND COMPANY
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.5 NOVARTIS AG
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 EXPANSION:
18.7 GENENTECH, INC. (A SUBSIDIARY OF A SUBSIDIARY OF F. HOFFMANN-LA ROCHE)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 LABORATORIO VARIFARMA SA
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.8.3.1 EXPANSION:
18.9 TUTEUR
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 CELNOVA PHARMA
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.10.3.1 PARTNERSHIP:
18.11 ERIOCHEM SA
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 GRUPO BIOTOSCANA
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENT
18.13 LABORATORIOS IMA
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
18.14 BRISTOL-MYERS SQUIBB COMPANY
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 SANOFI
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 2 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY STAGES , 2019-2028 (USD MILLION)
TABLE 3 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION)
TABLE 4 ARGENTINA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 5 ARGENTINA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 6 ARGENTINA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 7 ARGENTINA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 8 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 9 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2019-2028 (USD MILLION)
TABLE 10 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 11 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY END USERS, 2019-2028 (USD MILLION)
TABLE 12 ARGENTINA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 ARGENTINA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 2 ARGENTINA GASTRIC CANCER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ARGENTINA GASTRIC CANCER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ARGENTINA GASTRIC CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ARGENTINA GASTRIC CANCER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ARGENTINA GASTRIC CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ARGENTINA GASTRIC CANCER TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ARGENTINA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASED HEALTHCARE SPENDING AND THE RISE IN THE PREVALENCE OF TYPES OF GASTRIC CANCER ARE EXPECTED TO DRIVE THE ARGENTINA GASTRIC CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 ADENOCARCINOMA MARKET IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ARGENTINA GASTRIC CANCER TREATMENT MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ARGENTINA GASTRIC CANCER TREATMENT MARKET
FIGURE 14 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2020
FIGURE 15 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 16 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 17 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2020
FIGURE 19 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2021-2028 (USD MILLION)
FIGURE 20 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, CAGR (2021-2028)
FIGURE 21 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 22 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2020
FIGURE 23 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2021-2028 (USD MILLION)
FIGURE 24 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, CAGR (2021-2028)
FIGURE 25 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 26 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 28 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 29 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER 2020
FIGURE 31 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 32 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 33 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 36 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 ARGENTINA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 ARGENTINA GASTRIC CANCER TREATMENT MARKET: COMPANY SHARE 2020 (%)
